American Well Corporation ((AMWL)) has held its Q2 earnings call. Read on for the main highlights of the call.

Summer Sale - Claim 70% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

American Well Corp.’s latest earnings call struck a cautiously optimistic tone, as management balanced solid operational progress with notable revenue declines. Executives highlighted a strengthened balance sheet, improving profitability metrics, and growing subscription mix, but acknowledged that near‑term headwinds and contract timing risks leave the recovery story heavily dependent on execution.

Defense Health Agency win deepens strategic federal role

The centerpiece of the call was the Defense Health Agency’s intent to award Amwell a sole‑source contract, cementing its role within the Military Health System and the MHS GENESIS platform. Management framed the 3–5 year arrangement as proof that Amwell’s technology is now core federal health infrastructure, a milestone they believe will enhance credibility in future government and commercial bids.

Solid balance sheet offers runway with zero debt

Amwell ended Q2 with $196 million in cash and marketable securities and no debt, a key comfort point for investors worried about prolonged losses. Management argued this liquidity provides ample runway to execute its transformation plan and reach positive operating cash flow and adjusted EBITDA by Q4 2026 without needing to tap additional leverage.

Adjusted EBITDA nears breakeven as efficiency improves

Q2 adjusted EBITDA came in at a loss of about $1.15 million, sharply better than the $4.7 million loss a year earlier and the closest to breakeven since going public. Leaders reiterated their Q4 2026 target for positive adjusted EBITDA and operating cash flow, emphasizing ongoing cost discipline and operating leverage as subscription mix and higher‑value clinical programs scale.

Subscription revenue becomes majority despite YoY drop

Subscription revenue reached $25.7 million in Q2, now more than half of total sales and up roughly 3.2% sequentially, supporting a more predictable recurring model. Yet the year‑over‑year decline of about 36.5% underscored lingering churn and last year’s one‑time DHA benefit, leaving investors focused on whether new deals can offset the lost volume.

SilverCloud study delivers independent clinical validation

Management spotlighted a large randomized trial of its SilverCloud mental health platform published in Nature Human Behaviour, covering over 6,200 students with two‑year follow‑up. The study showed more than double engagement versus traditional care, fewer mental health disorders, and sizable avoided costs, bolstering the case that Amwell’s solutions deliver measurable value to payers and health systems.

Cost structure reset drives leaner operations

Total operating expenses fell to $37.1 million, down about 38% year over year and 18% sequentially, reflecting restructuring and tighter spending. Operating costs dropped to 71.3% of revenue from 84.8% a year earlier, a key driver of the improved EBITDA profile and a signal that the company’s transformation is materially reshaping its expense base.

AMG visit revenue rises with richer clinical mix

Amwell Medical Group generated $24.4 million of visit revenue, up roughly 7.4% year over year even as paid visits of about 315,000 were flat. Revenue per visit climbed to roughly $77, a 6% gain, as business shifted toward higher‑acuity programs and virtual primary care, with virtual primary care visits jumping around 30% and supporting stronger economics per encounter.

Guidance tightened as profitability outlook improves

Management narrowed full‑year 2026 revenue guidance to $200–$205 million and improved adjusted EBITDA expectations to a $9–$7 million loss, from a prior $16–$12 million range. The company framed this as growing confidence in its path to profitability, even as it acknowledged that near‑term results remain sensitive to project timing and seasonal visit patterns.

Topline under pressure from churn and visit declines

Q2 total revenue fell to $52 million, down about 26.6% from the prior year, weighed by earlier customer churn and the absence of a one‑time DHA subscription benefit booked last year. Total platform visits dropped to roughly 835,000, a decline of about 28.4%, highlighting significant volume contraction as Amwell reshapes its portfolio and focuses on higher‑value use cases.

Gross margin compresses despite sequential improvement

Gross profit reached $27.6 million, a 53% margin that was down roughly 310 basis points year over year from 56.1% but up about 200 basis points sequentially. Management linked the margin pressure to mix shifts and portfolio changes, while pointing to sequential gains as evidence that the new product and customer mix can stabilize profitability over time.

Near‑term Q3 pressure from project costs and seasonality

For Q3, Amwell guided revenue to $46–$48 million with an adjusted EBITDA loss of $5–$3 million, signaling a step‑down from Q2’s near‑breakeven result. Executives cited seasonal dynamics and completion costs for internal projects as temporary drags, expecting a recovery in Q4 as those expenses roll off and operating leverage resumes.

DHA contract timing and scope add uncertainty

While the DHA intent to award is a major strategic win, management cautioned that negotiations are ongoing and key deadlines have shifted, with a final date not until next year. They also noted potential expansions into areas like mental health may not show up in revenue until 2027, adding timing uncertainty to when this federal partnership translates into material topline growth.

2027 growth hinges on converting large pipeline deals

Looking further out, Amwell’s plan to return to double‑digit revenue growth in 2027 depends on closing significant government and payer contracts now in the pipeline. Management admitted that if these deals fail to materialize, the company’s revenue trajectory and operating leverage story would be weaker than envisaged, making execution on new contracts a central risk for investors.

Guidance underscores profitability focus amid revenue headwinds

The company’s outlook calls for Q3 2026 revenue of $46–$48 million and an adjusted EBITDA loss of $5–$3 million, alongside full‑year 2026 revenue of $200–$205 million and an improved adjusted EBITDA loss of $9–$7 million. With a reiterated goal of positive adjusted EBITDA and operating cash flow by Q4 2026, management is betting that cost discipline and higher‑value programs can offset the drag from current revenue declines.

Amwell’s earnings call painted a picture of a telehealth player in transition, trading short‑term revenue pressure for long‑term strategic positioning and improved efficiency. Investors will be watching closely to see whether the DHA opportunity and other pipeline deals convert into sustained growth, validating management’s profitability timeline and turning cautious optimism into a more convincing recovery story.